The regulatory distinction you made is so crucial: the July FDA advisory committee meeting on BPC-157, TB-500, KPV, and others is about compounding access through the 503A pathway, not approval, and not evidence of efficacy
The takeaway: Compounded pharmacies offer more affordable options for GLP-1 drugs, but there are increased risks that result in a "buyer-beware" market
Theres no published evidence on this combination
Evaluation of polyphenol anthocyanin-enriched extracts of blackberry, black raspberry, blueberry, cranberry, red raspberry, and strawberry for free radical scavenging, reactive carbonyl species trapping, anti-Glycation, anti--amyloid aggregation, and microglial Neuroprotective effects
The packaging is some of the most thoughtful Ive seen: cotton balls securing the vial, thick insulated foam, generous extra supplies, and ondansetron included proactively for nausea
Esosa decided to extend her nursing role and further her education because she believed she had more to offer to the nursing practice and patients